These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 10815931)

  • 1. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice.
    Feleszko W; Mlynarczuk I; Balkowiec-Iskra EZ; Czajka A; Switaj T; Stoklosa T; Giermasz A; Jakóbisiak M
    Clin Cancer Res; 2000 May; 6(5):2044-52. PubMed ID: 10815931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism.
    Feleszko W; Młynarczuk I; Olszewska D; Jalili A; Grzela T; Lasek W; Hoser G; Korczak-Kowalska G; Jakóbisiak M
    Int J Cancer; 2002 Jul; 100(1):111-8. PubMed ID: 12115596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.
    Holden SA; Lan Y; Pardo AM; Wesolowski JS; Gillies SD
    Clin Cancer Res; 2001 Sep; 7(9):2862-9. PubMed ID: 11555604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antitumor activity of tumor necrosis factor-alpha and lovastatin against MmB16 melanoma in mice.
    Feleszko W; Lasek W; Gołab J; Jakóbisiak M
    Neoplasma; 1995; 42(2):69-74. PubMed ID: 7617079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lovastatin enhances the antitumoral and apoptotic activity of doxorubicin in murine tumor models.
    Rozados VR; Hinrichsen LI; Binda MM; Gervasoni SI; Matar P; Bonfil RD; Scharovsky OG
    Oncol Rep; 2008 May; 19(5):1205-11. PubMed ID: 18425377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis.
    Feleszko W; Bałkowiec EZ; Sieberth E; Marczak M; Dabrowska A; Giermasz A; Czajka A; Jakóbisiak M
    Int J Cancer; 1999 May; 81(4):560-7. PubMed ID: 10225445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin.
    Sacchi A; Gasparri A; Curnis F; Bellone M; Corti A
    Cancer Res; 2004 Oct; 64(19):7150-5. PubMed ID: 15466213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs.
    Wang D; Li Y; Yu D; Song SS; Kandimalla ER; Agrawal S
    Int J Oncol; 2004 Apr; 24(4):901-8. PubMed ID: 15010828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of combinations of interferons and cytotoxic drugs in murine tumor models in vivo.
    Harrison SD; Stevens JJ; Waud WR; Dykes DJ; Schmid SM; Griswold DP
    J Biol Response Mod; 1990 Aug; 9(4):395-400. PubMed ID: 2118561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proapoptotic and antitumor activities of the HMG-CoA reductase inhibitor, lovastatin, against Dalton's lymphoma ascites tumor in mice.
    Ajith TA; Harikumar KB; Thasna H; Sabu MC; Babitha NV
    Clin Chim Acta; 2006 Apr; 366(1-2):322-8. PubMed ID: 16380106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
    Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
    Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice.
    Golab J; Stoklosa T; Czajka A; Dabrowska A; Jakobisiak M; Zagozdzon R; Wojcik C; Marczak M; Wilk S
    Anticancer Res; 2000; 20(3A):1717-21. PubMed ID: 10928098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
    Watanabe M; Komeshima N; Nakajima S; Tsuruo T
    Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model.
    Plum SM; Hanson AD; Volker KM; Vu HA; Sim BK; Fogler WE; Fortier AH
    Clin Cancer Res; 2003 Oct; 9(12):4619-26. PubMed ID: 14555538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
    Peer D; Dekel Y; Melikhov D; Margalit R
    Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin.
    Kozar K; Kaminski R; Legat M; Kopec M; Nowis D; Skierski JS; Koronkiewicz M; Jakóbisiak M; Golab J
    Int J Oncol; 2004 May; 24(5):1149-57. PubMed ID: 15067336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
    Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of lovastatin alone or combined with irradiation on tumor cells in vitro and in vivo.
    Gabryś D; Dörfler A; Yaromina A; Hessel F; Krause M; Oertel R; Baumann M
    Strahlenther Onkol; 2008 Jan; 184(1):48-53. PubMed ID: 18188523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.